1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors
ePostersLive by SciGen Technologies S.A. All rights reserved.
SOHO 2026 Annual Meeting
September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas
MM - 134
Durable Clinical Benefit of B-Cell Maturation Antigen (BCMA)-Directed Therapy With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (BPd) in Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-8 Long-Term Responder (LTR) Analysis
Poster Presenter
Authors
Part of Topic
Multiple Myeloma (MM)
Durable clinical benefit with BCMA-directed therapy, belantamab mafodotin plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: DREAMM-8 long-term responder analysis